Antibodies emerge as key focus for Kyowa Kirin
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin (KHK) is applying the technologies brought together by the merger of Kyowa Hakko and Kirin Pharma to an expanding pipeline of antibody products.
You may also be interested in...
Can Novartis Reclaim Pioneering Role In Transplantation?
Novartis is developing a new type of immunosuppressive agent, an anti-CD40 monoclonal antibody, which might allow organ transplants to last longer in recipients, reducing the pressure on transplant waiting lists and improving the long-term outlook for patients.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities.